TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9517644
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 250 mg q.i.d.
Study: 9517644
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 500 mg b.i.d.
Study: 9517644
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 500 mg b.i.d. and metronidazole 400 mg b.i.d. for the first 2 wk
Study: 16873325
Drug: Usual conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual conservative treatment (UT)
Study: 16873325
Drug: Self-care treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-care treatment without splint therapy (UT)
Study: 10672051
Drug: PCM-7 (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCM-7 (7 days of pantoprazole 40 mg bid, clarithromycin 500 mg bid, metronidazole 500 mg bid)
Study: 10672051
Drug: PCM-14 m
Normalized name: M
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCM-14 m (modified 14 day therapy with metronidazole only given for 10 days)
Study: 9280742
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride 100 mg p.o. or i.m. for moderate to intense pain
Study: 8149141
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg acyclovir orally four times daily during induction therapy
Study: 3521240
Drug: Dipyrone 575
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 575 mg
Study: 1626990
Drug: Tartrazine 50
Normalized name: tartrazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tartrazine 50 mg
Study: 29498050
Drug: Granulocyte transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte transfusion therapy plus antimicrobials
Study: 27687354
Drug: Flexed lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexed lateral position (L)
Study: 24757084
Drug: Ivabradine (Iva)
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ivabradine (Iva) 5 mg BID
Study: 24757084
Drug: Atenolol (Aten)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol (Aten) 12.5 mg BID
Study: 22493914
Drug: Aconite cake-separated
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aconite cake-separated moxibustion therapy with acupoints (Danzhong (CV 17), Zhongwan (CV 12), Guanyuan (CV 4), Dazhui (GV 14), Shenshu (BL 23), Mingmen (GV 4)) and oral administration of 25 microg Euthyrox everyday
Study: 22493914
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 25 microg Euthyrox everyday
Study: 12826990
Drug: Acamprosate 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 2 g/day
Study: 12826990
Drug: Acamprosate 3
Normalized name: acamprosate 333 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 3 g/day
Study: 12826990
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Naltrexone and Acamprosate)
Study: 12826990
Drug: Naltrexone and
Normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone and Acamprosate (both alone and in combination)
Study: 12826990
Drug: Combined medications
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medications
Study: 10821210
Drug: Alcohol pre-load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol pre-load (9 oz or 270 ml of beer)
Study: 1710922
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with eight cycles of MOPP
Study: 1710922
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MOPP and ABVD
Study: 1710922
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (including both arms)
Study: 1710922
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of relapsed patients
Study: 21942692
Drug: First-line antiretroviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line antiretroviral (ARV) treatment
Study: 17559147
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy with elevated serum HER-2/neu levels (>15 ng/mL) before treatment
Study: 17559147
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy with elevated serum HER-2/neu levels at 2 months
Study: 17559147
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy with changes in HER-2/neu levels between baseline and 2 months
Study: 17559147
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy with >or=20% increase of serum HER-2/neu
Study: 17559147
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy with kinetics of serum HER-2/neu
Study: 17559147
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy with low baseline serum levels of EGFR (<45 ng/mL)
Study: 17559147
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy with low baseline serum levels of EGFR
Study: 11955464
Drug: Yohimbine (.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (.4 mg/kg, IV)
Study: 9484152
Drug: MOD onlay
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: MOD onlay preparation
Study: 3926042
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of morphine
Study: 20297613
Drug: Oxycodone/acetaminophen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/acetaminophen (5 mg/325 mg, titrated for pain relief)
Study: 20297613
Drug: Oxycodone/acetaminophen (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/acetaminophen (mean daily dose 13.8 mg/720.4 mg)
Study: 18685961
Drug: Intrathecal thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal thoracic analgesia (ITA) with levobupivacaine 0.25%, at 0.5-0.7 ml/h, and a single bolus of morphine 0.15 mg
Study: 18685961
Drug: Epidural thoracic
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural thoracic analgesia (ETA) with levobupivacaine 0.25% 4-6 ml/h and a single bolus of epidural morphine 2-3 mg
Study: 15741443
Drug: Fluticasone 500
Normalized name: FLUTICASONE 500MCG/SALMETEROL 50MCG INHL,ORAL,DISKUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 500 mug twice daily
Study: 12515837
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (6 weekly sessions)
Study: 12515837
Drug: Supportive psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive psychotherapy (6 weekly sessions)
Study: 10916110
Drug: Hydrosoluble vitamins
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrosoluble vitamins (DiaVite) supplementation once daily by mouth
Study: 10916110
Drug: Intravenous folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous folic acid (10 mg posthemodialysis, 30 mg per week) in addition to DiaVite
Study: 10916110
Drug: Intravenous folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous folic acid (10 mg posthemodialysis, 30 mg per week)
Study: 8873685
Drug: Rifampin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (300 mg b.i.d. for 7 days)
Study: 8873685
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg q.i.d. for 7 days)
Study: 1647387
Drug: Interactive information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive information system with instructional video programs, feedback on purchases, specific goals for change, weekly programs, and tracking user interactions; duration: 7-8 weeks intervention phase after a 5-7 week baseline phase.
Study: 27287439
Drug: Ovaleap® (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovaleap® (recombinant human follicle-stimulating hormone) administered for up to 2 additional cycles
Study: 8953337
Drug: 6.9% glucose-polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.9% glucose-polymer (GP) solution
Study: 17135583
Drug: Episodic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic use of antiretroviral therapy (drug conservation group)
Study: 17135583
Drug: Continuous use
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous use of antiretroviral therapy (viral suppression group)
Study: 8835583
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of rifampicin
Study: 8835583
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of rifampicin
Study: 23602244
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (37.4 mg of elemental iron daily for 12 weeks)
Study: 21747102
Drug: No pills
Normalized name: No Doz Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pills
Study: 21747102
Drug: Blinded to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded to placebo vs No pills
Study: 21747102
Drug: Subgroup (rated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup (rated echinacea's effectiveness >50) - Blinded to placebo vs No pills
Study: 21437714
Drug: almotriptan 12.5
Normalized name: almotriptan 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: almotriptan 12.5 mg
Study: 15611510
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m² plus paclitaxel 200 mg/m² (AP)
Study: 11426769
Drug: Bovine and
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine and porcine heparin
Study: 7744133
Drug: Diclofenac/misoprostol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac/misoprostol (50 mg/200 mcg) administered BID or TID (n = 177)
Study: 7744133
Drug: Diclofenac/placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac/placebo (50 mg) administered BID or TID (n = 169)
Study: 4936538
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with phenothiazines
Study: 22243938
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (HSS) 100mL (NaCl 7.5%) twice daily for three days
Study: 18838979
Drug: High-Ca diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Ca diet (2300 mg Ca per d)
Study: 18838979
Drug: Low-Ca diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Ca diet (700 mg Ca per d)
Study: 12705061
Drug: Selective cyclooxygenase-2
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective cyclooxygenase-2 inhibitors (e.g., celecoxib, rofecoxib, parecoxib)
Study: 12705061
Drug: Classic non-steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic non-steroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen)
Study: 8292679
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage (2.25 T)
Study: 2853164
Drug: Granular porous
Normalized name: Saxifraga granulata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granular porous hydroxylapatite implants
Study: 2853164
Drug: Solid porous
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid porous hydroxylapatite implants
Study: 31490817
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 1 µg/mL (group P1)
Study: 31490817
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 2 µg/mL (group P2)
Study: 31490817
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 3 µg/mL (group P3)
Study: 31490817
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 to 3 µg/mL)
Study: 22248760
Drug: Epidural S(+)-ketamine
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural S(+)-ketamine with 0.25% bupivacaine (13 mL + 25 mg) before incision
Study: 22248760
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution before incision followed by epidural S(+)-ketamine with 0.25% bupivacaine (13 mL + 25 mg) after incision
Study: 16284537
Drug: Preventive HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive HIV vaccine trial
Study: 9789590
Drug: Glimepiride, Repaglinide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride, Repaglinide, Glucagon-like peptide I (drugs stimulating insulin secretion)
Study: 9789590
Drug: Thiazolidinediones (medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinediones (medications reducing insulin resistance)
Study: 9789590
Drug: Vanadium (insulin-mimetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanadium (insulin-mimetic agents)
Study: 9789590
Drug: Alpha glucosidase
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha glucosidase inhibitors
Study: 30793734
Drug: Dabigatran dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran dual therapy
Study: 19341987
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate 15mg/day capsules
Study: 17298975
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) in small stents/bypass grafts
Study: 17298975
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) in other patients
Study: 12791056
Drug: Insecticide-treated synthetic-netting
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insecticide-treated synthetic-netting ceiling (deltamethrin 12.5 mg/m2)
Study: 10522581
Drug: Ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5 mg x ml(‐1)
Study: 10522581
Drug: Bupivacaine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5.0 mg x ml(‐1)
Study: 1723814
Drug: Alfuzosine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosine 2.5 mg x 3
Study: 7048251
Drug: Captopril-labetalol combination
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril-labetalol combination treatment
Study: 25278227
Drug: Nine-valent human
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine-valent human papillomavirus vaccine (selected dose formulation)
Study: 25278227
Drug: Four-valent human
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-valent human papillomavirus vaccine (active control)
Study: 25278227
Drug: Four-valent human
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-valent human papillomavirus vaccine
Study: 16776928
Drug: Midazolam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (7.5 ‐ 15 mg before sleep, n = 113)
Study: 16776928
Drug: Estazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam (1 ‐ 2 mg before sleep, n = 104)
Study: 10856535
Drug: Atorvastatin 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 120 mg/day
Study: 10856535
Drug: Atorvastatin 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 160 mg/day
Study: 9021345
Drug: Agnus castus
Normalized name: Vitex agnus-castus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agnus castus extract (BP1095E1) 120 mg/day
Study: 9021345
Drug: Agnus castus
Normalized name: Vitex agnus-castus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agnus castus extract (BP1095E1) 240 mg/day
Study: 9021345
Drug: Agnus castus
Normalized name: Vitex agnus-castus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agnus castus extract (BP1095E1) 480 mg/day
Study: 2676121
Drug: Verapamil (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (320 mg/day)
Study: 28891027
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate monohydrate 3 mg/kg twice a day orally for 10 days along with standard antibiotics
Study: 28891027
Drug: No zinc
Normalized name: ZINC OXIDE 140 mg in 1 mL TOPICAL CREAM [Lucin Organics Tinted Sunscreen SPF 30 Non Nano Zinc Oxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No zinc (antibiotic treatment only)
Study: 20798191
Drug: Sunscreen with
Normalized name: ZINC OXIDE 0.1995 g in 1 g TOPICAL CREAM [SilkShield All Mineral Sunscreen with TriHex Technology]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen with SPF 60 applied twice a day for 28 days
Study: 16983914
Drug: Shenmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai Injection (SMI) 30 ml once a day for 10 days
Study: 16983914
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus NPPV (Control)
Study: 12452216
Drug: Sufentanil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.5 microg/kg administered prior to skin incision, median sternotomy, CPB, and after coming off CPB
Study: 12452216
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 mg/kg administered at the same time periods as sufentanil
Study: 10626336
Drug: Movalis 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movalis 7.5 mg
Study: 10626336
Drug: Movalis 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movalis 15 mg
Study: 10626336
Drug: Movalis (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movalis (dose increased from 7.5 mg to 15 mg in poor responders)
Study: 1981434
Drug: Active grenz
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active grenz ray therapy (4 Gy, 10 kV, applied 6 times at 1-week intervals)
Study: 1981434
Drug: Stimulated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulated therapy (control)
Study: 6757467
Drug: Bacillus Calmette‐Guerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette‐Guerin (BCG) immunotherapy
Study: 25338776
Drug: Imipramine or
Normalized name: imipramine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine or venlafaxine (antidepressants)
Study: 24518937
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg orally 2 hours before surgery and 12.5 mg of heavy bupivacaine 0.5% intrathecally
Study: 24518937
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 10 μg plus 12.5 mg of heavy bupivacaine 0.5%
Study: 17519078
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Alutard SQ (ASQ)
Study: 31994278
Drug: Nutraceutical compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical compound containing Ilex paraguariensis, White Mulberry and Chromium Picolinate (500 mg), taken once a day for 3 months.
Study: 19933412
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (GTN; 0.6 mg/h) for 2 hours on 1 day only
Study: 19933412
Drug: Transdermal GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal GTN for 2 hours/day for 7 days
Study: 19933412
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with transdermal GTN for 7 days
Study: 19933412
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of vitamin C after continuous GTN therapy
Study: 12903463
Drug: Gossypol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gossypol (15 mg/d for 12 weeks, then 10 mg/d for 32 weeks)
Study: 9333168
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (2 mL of 720 ELISA units/mL) given to HIV-infected men either 1 or 6 months apart; HIV-uninfected men received vaccine at study entry and at 6 months.
Study: 3096634
Drug: Levonorgestrel and
Normalized name: levonorgestrel and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel and Ethinyl Estradiol as an oral tablet
Study: 3096634
Drug: Levonorgestrel and
Normalized name: levonorgestrel and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel and Ethinyl Estradiol as a solution